Hereditary Spastic Paraplegia 56 (SPG56) Cell Models for Research

Hereditary Spastic Paraplegia 56 (SPG56) is a rare autosomal recessive neurodegenerative disorder characterized by progressive spasticity and weakness of the lower limbs. The prevalence of hereditary spastic paraplegias (HSPs) is estimated at 1-10 per 100,000 individuals worldwide, with SPG56 accounting for a small fraction of cases. Onset typically occurs in childhood or adolescence, leading to progressive disability. There is no cure, and current management is symptomatic. The disease imposes a significant burden on patients and families, with a need for disease-modifying therapies.

SPG56 is an ideal model for studying axonal degeneration and mitochondrial dysfunction. The disease is caused by mutations in CYP2U1, a gene involved in fatty acid metabolism. Research models help elucidate the molecular mechanisms underlying neurodegeneration, identify potential therapeutic targets, and test gene therapy approaches. Public datasets and patient-derived cell lines facilitate functional studies.

SPG56 is primarily caused by mutations in CYP2U1, which encodes a cytochrome P450 enzyme involved in the metabolism of arachidonic acid and other fatty acids. The pathogenic mechanisms include:

• • Mitochondrial dysfunction: CYP2U1 localizes to mitochondria and its deficiency leads to impaired oxidative phosphorylation and increased oxidative stress.
• • Altered lipid metabolism: Disruption of fatty acid hydroxylation affects membrane composition and signaling.
• • Axonal transport defects: Mitochondrial dysfunction impairs axonal transport, leading to dying-back axonopathy.
• • Calcium homeostasis disruption: Mitochondrial dysfunction can affect calcium buffering, leading to neuronal damage.

Key signaling networks affected in SPG56 include:

• • Mitochondrial biogenesis and dynamics: PGC-1α, MFN2, DRP1
• • Oxidative stress response: NRF2, SOD2
• • Lipid metabolism: PPARs, SREBPs
• • Axonal transport: Kinesin and dynein motors
• • Neuroinflammation: TNF-α, IL-6

Organoids, such as cerebral organoids, can recapitulate neuronal development and are useful for studying SPG56 pathology.

• • CYP2U1 knockout mice: Show motor deficits and mitochondrial abnormalities.
• • Zebrafish models: Used for drug screening and gene function studies.
• • Drosophila models: Useful for genetic interaction studies.
• • Patient-derived xenografts (PDX): Not applicable for neurodegenerative diseases, but relevant for cancer models.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with specific CYP2U1 mutations. For example:

• • CYP2U1 knockout cell lines: Complete loss of function to study null phenotypes.
• • CYP2U1 point mutation knock-in lines: Mimic patient-specific mutations (e.g., p.Arg376Trp).
• • Reporter lines: Tagged with GFP or luciferase to monitor gene expression.

These models are commercially available from various sources, sequence-verified, and quality-controlled, accelerating research without the need for in-house gene editing.

Knockout and knock-in lines are used to validate the function of CYP2U1 and identify interacting partners. For example:

• • Transcriptomic analysis of CYP2U1 knockout cells reveals dysregulated genes involved in mitochondrial function.
• • Proteomic studies identify altered protein complexes.
• • CRISPR screens can identify genetic modifiers that rescue or exacerbate the phenotype.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput screens to identify compounds that selectively affect mutant cells. This can lead to the discovery of drugs that rescue mitochondrial dysfunction or compensate for CYP2U1 loss. Resistance mechanisms can be studied by exposing cells to increasing concentrations of drugs.

CRISPR-engineered cells can be used to identify biomarkers for disease progression or treatment response. For example, secreted metabolites or proteins that are altered in mutant cells could serve as biomarkers. Synthetic lethality screens can identify genes that are essential only in the mutant context, providing potential therapeutic targets.